Coaxing iPS cells to become more specialized prior to transplantation cuts rejection risk, study shows

A new study shows that coaxing iPS cells in the laboratory to become more-specialized cells before transplantation into mice allows them to be tolerated by the body's immune system.

Joseph Wu

For many scientists, the clinical promise of stem cells has been dampened by very real concerns that the immune system will reject the transplanted cells before they could render any long-term benefit. Previous research in mice has suggested that even stem cells produced from the subject’s own tissue, called iPS cells, can trigger an immune attack.

Now researchers at the Stanford University School of Medicine have found that coaxing iPS cells in the laboratory to become more-specialized progeny cells (a cellular process called differentiation) before transplantation into mice allows them to be tolerated by the body’s immune system.

“Induced pluripotent stem cells have tremendous potential as a source for personalized cellular therapeutics for organ repair,” said Joseph Wu, MD, PhD, director of the Stanford Cardiovascular Institute. “This study shows that undifferentiated iPS cells are rejected by the immune system upon transplantation in the same recipient, but that fully differentiating these cells allows for acceptance and tolerance by the immune system without the need for immunosuppression.”

The findings are described in a paper published online May 30 in Nature Communications. Wu is senior author of the paper. Postdoctoral scholars Patricia Almeida, PhD, and Nigel Kooreman, MD, and assistant professor of medicine Everett Meyer, MD, PhD, share lead authorship.

The body's watchdog

In a world teeming with microbial threats, the immune system is a necessary watchdog. Immune cells patrol the body looking not just for foreign invaders, but also for diseased or cancerous cells to eradicate. The researchers speculate that the act of reprogramming adult cells to pluripotency may induce the expression of cell-surface molecules the immune system has not seen since the animal (or person) was an early embryo. These molecules, or antigens, could look foreign to the immune system of a mature organism.

Previous studies have suggested that differentiation of iPS cells could reduce their tendency to inflame the immune system after transplantation, but this study is the first to closely examine, at the molecular and cellular level, why that might be the case.

“We’ve demonstrated definitively that, once the cells are differentiated, the immune response to iPS-derived cells is indistinguishable from its response to unmodified tissue derived from elsewhere in the body,” said Kooreman.

Pluripotent stem cells, by definition, can give rise to any cell in the body. Although embryonic stem cells are naturally pluripotent, iPS cells are created by scientists from existing adult cells, such as skin or blood. They are easier than embryonic stem cells to come by and they match the genetic background of the person from whom they were obtained. In theory, they’re a good option for a physician wishing to generate patient-specific stem cells for potential therapies.

Previous studies in mice have shown, however, that even genetically identical iPS cells can trigger an immune response after transplantation. For the past six years, the Wu laboratory has been investigating how to use immunosuppressive medications to dampen the body’s response to both embryonic and induced pluripotent stem cells to render them more amenable for clinical use.

In this recent study, Kooreman and his co-lead authors decided to look more closely at the immune response to transplanted stem cells. They first transplanted undifferentiated iPS cells into the leg muscles of genetically identical recipient mice. As expected, these grafts were rejected and no iPS cells could be detected by about 42 days after transplantation.

The researchers then differentiated the iPS cells into endothelial cells, which line the interior of the heart and blood vessels, before transplantation. They compared the acceptance of these iPS-derived endothelial cells with that of naturally occurring endothelial cells derived from the aortic lining of donor mice. As with the previous experiment, all the transplanted cells were genetically identical to the mice in which they were injected.

Longer cell survival

Unlike the undifferentiated iPS cells, though, both the iPS-derived endothelial cells and the aortic endothelial cells survived for at least 63 days after transplantation.

Next, the researchers repeated the experiment, but removed the grafts 15 days after transplantation. They found that although immune cells called lymphocytes were present in all grafts, they were much more prevalent in the grafts of undifferentiated iPS cells. Lymphocytes in the grafts of undifferentiated iPS cells were also expressing relatively high levels of genes known to be involved in hostile immune responses. In contrast, lymphocytes in both types of endothelial cell grafts expressed higher levels of genes known to be involved in dampening the immune response and inducing self-tolerance.

Finally, the researchers directly examined a type of lymphocyte called a T cell. They found that, while the grafts of undifferentiated iPS cells harbored large numbers of T cells of only a few specificities — indicating a robust immune response — those found in grafts of the two types of endothelial cells were more diverse, suggesting a more limited response associated with a phenomenon known as self-tolerance.

“The immune response to the iPS-derived endothelial cells and the aortic endothelial cells, and the longevity of the grafts, was very similar,” said Kooreman. “If we specifically look at the T cells, we see they’re also very similar and that they look much different from grafts that are rejected.”

Wu, who is also a professor of cardiovascular medicine and of radiology, said, “This study certainly makes us optimistic that differentiation — into any nonpluripotent cell type — will render iPS cells less recognizable to the immune system. We have more confidence that we can move toward clinical use of these cells in humans with less concern than we’ve previously had.”

Other Stanford authors of the study are postdoctoral scholars Sebastian Diecke, PhD, Devaveena Dey, PhD, Antje Ebert, PhD, and David Lo, MD; research associate Veronica Sanchez-Freire, PhD; instructors Shijun Hu, PhD, and Justin Odegaard, MD, PhD; former postdoctoral scholar Nicholas Mordwinkin, PhD; medical student Thomas Brouwer; research assistant Daniel Montoro; professor of surgery Michael Longaker, MD; and professor of medicine Robert Negrin, MD.

The research was supported by the California Institute for Regenerative Medicine, the National Institutes of Health (grants AI085575 and HL099776), the Oak Foundation, the Hagey Laboratory for Pediatric Regenerative Medicine, the International Society for Heart and Lung Transplantation, and the American Society for Blood and Marrow Transplantation.

Information about Stanford’s Department of Medicine, which also supported the work, is available at http://medicine.stanford.edu.

 



Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.